Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy

Biomedicine and Pharmacotherapy

Volumn 67, Issue 1, 2013, Pages 39-42

  Tatsushima, Yoko ^a   Egashira, Nobuaki ^a   Narishige, Yuri ^a   Fukui, Shiori ^a   Kawashiri, Takehiro ^a   Yamauchi, Yui ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Calcium channel blocker; Chemotherapy; Colorectal cancer; Oxaliplatin; Peripheral neuropathy

Indexed keywords

AMLODIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; DILTIAZEM; FLUOROURACIL; FOLINIC ACID; NIFEDIPINE; NILVADIPINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM CHANNEL BLOCKERS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES;

EID: 84873078761     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.006     Document Type: Article

References (34)

1. Pasetto L.M., D'Andrea M.R., Rossi E., Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 2006, 59:159-168.
2. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9-17.
3. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-1774.
4. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005, 5(1):S38-S46.
5. Extra J.M., Marty M., Brienza S., Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998, 25:13-22.
6. Berretta M., Taibi R., Bearz A., La Mura N., Berretta S., Tirelli U., et al. Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy. J Chemother 2004, 16:595-598.
7. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
8. Hill A., Bergin P., Hanning F., Thompson P., Findlay M., Damianovich D., et al. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 2010, 10:451.
9. Kawashiri T., Egashira N., Watanabe H., Ikegami Y., Hirakawa S., Mihara Y., et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain 2011, 15:344-350.
10. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000, 406:25-32.
11. + channels in frog peripheral myelinated axons. Gen Physiol Biophys 2006, 25:263-276.
12. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293-2297.
13. Kagiava A., Tsingotjidou A., Emmanouilides C., Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008, 29:1100-1106.
14. Grothey A., Nikcevich D.A., Sloan J.A., Kugler J.W., Silberstein P.T., Dentchev T., et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011, 29:421-427.
15. Kurniali P.C., Luo L.G., Weitberg A.B. Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology (Williston Park) 2010, 24:289-292.
16. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
17. Rao R.D., Michalak J.C., Sloan J.A., Loprinzi C.L., Soori G.S., Nikcevich D.A., et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110:2110-2118.
18. Sakurai M., Egashira N., Kawashiri T., Yano T., Ikesue H., Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 2009, 147:165-174.
19. Gauchan P., Andoh T., Kato A., Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 2009, 458:93-95.
20. McKemy D.D., Neuhausser W.M., Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002, 416:52-58.
21. Peier A.M., Moqrich A., Hergarden A.C., Reeve A.J., Andersson D.A., Story G.M., et al. A TRP channel that senses cold stimuli and menthol. Cell 2002, 108:705-715.
22. 2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain 2012, 8:7.
23. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005, 5(Suppl 1):S38-S46.
24. Nishioka M., Shimada M., Kurita N., Iwata T., Morimoto S., Yoshikawa K., et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 2011, 16:322-327.
25. Watson C.P., Moulin D., Watt-Watson J., Gordon A., Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003, 105:71-78.
26. Yaqub B.A., Siddique A., Sulimani R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg 1992, 94:105-111.
27. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005, 39:128-135.
28. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269-1275.
29. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000, 6:1205-1218.
30. Gamelin L., Boisdron-Celle M., Delva R., Guérin-Meyer V., Ifrah N., Morel A., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055-4061.
31. Berkley K.J. Sex differences in pain. Behav Brain Sci 1997, 20:371-380. [discussion 435-513].
32. Goldberg R.M., Tabah-Fisch I., Bleiberg H., de Gramont A., Tournigand C., Andre T., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24:4085-4091.
33. Sugimoto S., Katano K., Kanazawa A., Yoshimura H., Kidani A., Takeda H., et al. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. J Exp Clin Cancer Res 2009, 28:109.
34. Syrigos K.N., Karapanagiotou E., Boura P., Manegold C., Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011, 25:159-169.